References
- Peppercorn J. The financial burden of cancer care: do patients in the US know what to expect? Expert Rev Pharmacoecon Outcomes Res. 2014;14(6):835–842.
- Scalo JF, Rascati KL. Trends and issues in oncology costs. Expert Rev Pharmacoecon Outcomes Res. 2014;14(1):35–44.
- Vogler S, Vitry A, Babar Z-U-D. Cancer drugs in 16 European countries, Australia, and New Zealand: a cross-country price comparison study. Lancet Oncol. 2016;17(1):39–47.
- Van Harten WH, Wind A, De Paoli P, et al. Actual costs of cancer drugs in 15 European countries. Lancet Oncol. 2016;17(1):18–20. .
- WHO. Technical report: pricing of cancer medicines and its impacts: a comprehensive technical report for the World Health Assembly Resolution 70.12: operative paragraph 2.9 on pricing approaches and their impacts on availability and affordability of medicines for the prevention and treatment of cancer. Geneva: World Health Organization; 2018.
- Eichler H-G, Hurts H, Broich K, et al. Drug regulation and pricing — can regulators influence affordability? N Engl J Med. 2016;374(19):1807–1809.
- Janzic U, Knez L, Janzic A, et al. Time to access to novel anticancer drugs and the correlation with ESMO-Magnitude of Clinical Benefit Scale in Slovenia. Expert Rev Pharmacoecon Outcomes Res. 2019;19(6):717–723.
- Davis C, Naci H, Gurpinar E, et al. Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13. BMJ. 2017;359:j4530. .
- Del Paggio JC, Sullivan R, Schrag D, et al. Delivery of meaningful cancer care: a retrospective cohort study assessing cost and benefit with the ASCO and ESMO frameworks. Lancet Oncol. 2017;18(7):887–894. .
- Vokinger KN, Hwang TJ, Grischott T, et al. Prices and clinical benefit of cancer drugs in the USA and Europe: a cost–benefit analysis. Lancet Oncol. 2020;21(5):664–670. .
- Saluja R, Arciero VS, Cheng S, et al. Examining trends in cost and clinical benefit of novel anticancer drugs over time. J Oncol Pract. 2018;14(5):e280–e94. .
- Salas-Vega S, Shearer E, Mossialos E. Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Soc Sci Med. 2020;258:113042.
- WHO. Model list of essential medicines. Geneva: World Health Organization, 2020. (Accessed 2021 Jan 11). Available from: https://list.essentialmeds.org/?indication=91
- WHO. Essential medicines. Geneva: World Health Organization, 2021. (Accessed 2021 Jan 2). Available from: https://www.who.int/topics/essential_medicines/en/
- United Nations. Sustainable Development Goals (SDG). Geneva, 2020.(Accessed 2020 Aug 23). Available from: https://www.un.org/sustainabledevelopment/health/
- Høie B The effect of cancer medicine prices on national healthcare budgets & the need for more cooperation. Welcome address at the Launch of the European Fair Pricing Network (EFPN). 30 November 2020. Online event: EFPN, 2020. (Accessed and Transcripted 2021 Jan 12). Available from: https://www.youtube.com/watch?v=L2eiUY_yq8g
- Schneider P, Vogler S. Practice of external price referencing. In: Vogler S, editor. Medicine Price Surveys, Analyses and Comparisons. London: Elsevier; 2019. p. 345–368.
- Espin J, Rovira J, De Labry AO Working paper 1: external price referencing – review series on pharmaceutical pricing policies and interventions. Geneva: World Health Organization and Health Action International, 2011. (Accessed 2021 Feb 7). Available from: http://www.haiweb.org/medicineprices/24072012/ERPfinalMay2011.pdf
- Espin J, Rovira J, Ewen M, et al. Mapping external reference pricing practices for medicines. Health Action International (HAI), 2014.
- Rémuzat C, Urbinati D, Mzoughi O, et al. Overview of external reference pricing systems in Europe. J Mark Access Health Policy. 2015;3:27675. DOI:10.3402/jmahp.v3.27675.
- Ibrahim MI, Rida NM, Babar Z, et al. Pharmaceutical pricing strategies in developing countries: a systematic review. Value Health. 2016;19(7):A455.
- Kaló Z, Alabbadi I, Al Ahdab OG, et al. Implications of external price referencing of pharmaceuticals in Middle East countries. Expert Rev Pharmacoecon Outcomes Res. 2015;15(6):993–998. .
- Babar ZUD. Pharmaceutical prices in the 21st century. Cham Heidelberg New York Dordrecht London: Springer; 2015.
- Nguyen TA, Knight R, Roughead EE, et al. Policy options for pharmaceutical pricing and purchasing: issues for low- and middle-income countries. Health Policy Plann. 2015;30(2):267–280.
- PAHO. Access to High-Cost Medicines in the Americas Situation, Challenges and Perspectives. Washington D.C: Pan American Health Organization, 2010. (Accessed 2020 Aug 20). Available from: https://www.paho.org/hq/dmdocuments/2010/High-cost-Med-Tech-Series-No-1-Sep-15-10.pdf
- Vogler S, Zimmermann N, Haasis MA PPRI Report 2018: pharmaceutical pricing and reimbursement policies in 47 PPRI network member countries Vienna: WHO Collaborating Centre for Pricing and Reimbursement Policies, Gesundheit Österreich GmbH (GÖG/Austrian National Public Health Institute), 2019. (Accessed 2020 Aug 23). Available from: https://ppri.goeg.at/sites/ppri.goeg.at/files/inline-files/PPRI%20Report2018_2nd_edition_final.pdf
- Persson U, Jönsson B. The end of the international reference pricing system? Appl Health Econ Health Policy. 2016;14(1):1–8. .
- Kyle MK. Pharmaceutical price controls and entry strategies. Rev Econ Stat. 2007;89(1):88–99.
- Danzon PM, Epstein AJ. Effects of regulation on drug launch and pricing in interdependent markets. Adv Health Econ Health Serv Res. 2012;23:35–71.
- Vogler S, Schneider P, Zimmermann N. Evolution of average European medicine prices: implications for the methodology of external price referencing. Pharmacoecon Open. 2019;3(3):303–309.
- Vogler S. Medicines pricing: limitations of existing policies and new models. In: Babar Z-U-D, editor. Global Pharmaceutical Policy. Singapore: Palgrave Macmillan; 2020. p. 99–137.
- Pauwels K, Huys I, Vogler S, et al. Managed entry agreements for oncology drugs: lessons from the European experience to inform the future. Front Pharmacol. 2017;171(8).
- Ferrario A, Arāja D, Bochenek T, et al. The implementation of managed entry agreements in Central and Eastern Europe: findings and implications. Pharmacoeconomics. 2017;35(12):1271–1285. .
- Gamba S, Pertile P, Vogler S. The impact of managed entry agreements on pharmaceutical prices. Health Econ. 2020;29(S1):47–62. .
- Public Eye. Keine geheimen Rabatte auf Medikamente (No secret discounts on medicines). 2020. (Accessed 2021 Feb 7). Available from: https://www.publiceye.ch/de/news/detail/keine-geheimen-rabatte-auf-medikamente
- Vogler S, Paterson KR. Can price transparency contribute to more affordable patient access to medicines? Pharmacoecon Open. 2017;1(3):145–147.
- Mardetko N, Kos M, Vogler S. Review of studies reporting actual prices for medicines. Expert Rev Pharmacoecon Outcomes Res. 2019;19(2):159-179.
- Russo P, Mennini FS, Siviero PD, et al. Time to market and patient access to new oncology products in Italy: a multistep pathway from European context to regional health care providers. Ann Oncol. 2010;21(10):2081–2087.
- Makady A, Van Veelen A, De Boer A, et al. Implementing managed entry agreements in practice: the Dutch reality check. Health Policy. 2019;123(3):267–274.
- Dranitsaris G, Zhu X, Adunlin G, et al. Cost effectiveness vs. affordability in the age of immuno-oncology cancer drugs. Expert Rev Pharmacoecon Outcomes Res. 2018;18(4):351–357.
- Huff-Rousselle M. The logical underpinnings and benefits of pooled pharmaceutical procurement: a pragmatic role for our public institutions? Soc Sci Med. 2012;75(9):1572–1580.
- Drummond M, Jönsson B. Moving beyond the drug budget silo mentality in Europe. Value Health. 2003;6(s1):S74–S7.
- Buxton M, Longworth L, Raftery J, et al. Reforming the cancer drug fund focus on drugs that might be shown to be cost effective. BMJ. 2014;349(nov28 2):g7276.
- Chamberlain C, Collin S, Stephens P, et al. Does the cancer drugs fund lead to faster uptake of cost-effective drugs? A time-trend analysis comparing England and Wales. Br J Cancer. 2014;111(9):1693.
- Paulden M Recent amendments to NICE’s value-based assessment of health technologies: implicitly inequitable?: Taylor & Francis; 2017.
- Simoens S. How do biosimilars sustain value, affordability, and access to oncology care? Expert Rev Pharmacoecon Outcomes Res. 2020;1–3. DOI:10.1080/14737167.2020.1813570.
- Stiff KM, Cline A, Feldman SR. Tracking the price of existing biologics when drugs enter the market. Expert Rev Pharmacoecon Outcomes Res. 2019;19(4):375–377.
- WHA. Resolution WHA 72.8: improving the transparency of markets for medicines, vaccines, and other health products. 28 May 2019. Geneva: World Health Assembly, 2019. (Accessed 2020 Oct 5). Available from: http://apps.who.int/gb/ebwha/pdf_files/WHA72/A72_ACONF2Rev1-en.pdf
- Moon S, Mariat S, Kamae I, et al. Defining the concept of fair pricing for medicines. BMJ. 2020;368:l4726.
- WHO. Report on the Fair Pricing Forum 2017. Geneva: World Health Organization; 2017.
- WHO. Fair pricing forum 2019 meeting report: Johannesburg, South Africa, 11–13 April 2019. World Health Organization, 2019. (Accessed 2021 Jan 11). Available from: https://apps.who.int/iris/bitstream/handle/10665/326407/WHO-MVP-EMP-IAU-2019.09-eng.pdf
- Suleman F, Low M, Moon S, et al. New business models for research and development with affordability requirements are needed to achieve fair pricing of medicines. BMJ. 2020;368:l4408.
- Rintoul A, Colbert A, Garner S, et al. Medicines with one seller and many buyers: strategies to increase the power of the payer. BMJ. 2020;369:m1705.
- Ferrario A, Dedet G, Humbert T, et al. Strategies to achieve fairer prices for generic and biosimilar medicines. BMJ. 2020;368:368.
- WHO EURO. The Oslo Medicines Initiative. Copenhagen: World Health Organization Regional Office for Europe, 2020. (Accessed 2020 Dec 29). Available from: https://www.euro.who.int/en/health-topics/Health-systems/health-technologies-and-medicines/the-oslo-medicines-initiative
- EFPN. European Fair Pricing Network. Amsterdam: European Fair Pricing Network, 2020. (Accessed 2021 Jan 13). Available from: https://www.kwf.nl/sites/default/files/2020-11/About%20EFPN_1pager.pdf
- Federal Ministry of Health and Women, Main Association of the Austrian Social Health Insurance institutions, Austrian provinces. Zielsteuerungsvertrag auf Bundesebene. Zielsteuerung-Gesundheit 2017–2021 (Target conrol contract at federal level. Target control - Health 2017–2021). Vienna, 2017. (Accessed 2020 Jan 13). Available from: https://www.sozialministerium.at/dam/jcr:ae2cd2c2-dc03-44ba-9a15-47826081189f/Zielsteuerungsvertrag%20auf%20Bundesebene%20Stand%2005.05.2017%20BF1.pdf
- Euripid Collaboration. Euripid. About us. 2021. (Accessed 2021 Jan 13). Available from: https://euripid.eu/aboutus
- European Parliament. Options for improving access to medicines. European Parliament resolution of 2 March 2017 on EU options for improving access to medicines (2016/2057(INI)). 2017. (Accessed 2021 Jan 13). Available from: https://eur-lex.europa.eu/legal-content/EN/TXT/PDF/?uri=CELEX:52017IP0061&from=EN
- Vogler S, Haasis MA, Van Den Ham R, et al. Cross-Country Collaborations to improve access to medicines and vaccines in the WHO European Region. Word Health Organization Regional Office for Europe, 2020. (Accessed 2020 Jul 16) Available from: https://apps.who.int/iris/bitstream/handle/10665/332933/9789289055031-eng.pdf